Parameter | Valuea | Sources | Note | |
---|---|---|---|---|
Women | Men | |||
Probabilities | ||||
VF prevalence | 0.22 [0.08] | 0.11 [0.03] | NHI database [Community-based cohort] | |
two-year VF incidence | 0.12 [0.13] | 0.05 [0.05] | HIRA, [32] | NHI database [Community-based cohort] |
two-year new VF incidence | 0.22 [0.23] | 0.22 [0.23] | Hospital cohort- NHI database linked data [Community-based cohort] | |
RR of new VF on drug therapy | 0.58 [0.64] | 0.38 [0.41] | Meta-analysis literature review, pooled RR [decrease by 10%] | |
Diagnostic accuracy | ||||
Sensitivity of X-ray | 1.00 | 1.00 | Gold standard | |
Specificity of X-ray | 1.00 | 1.00 | Gold standard | |
Sensitivity of VFA | 0.82 [0.74] | 0.82 [0.74] | [22] | SR [95% CI lower limit, conservative] |
Specificity of VFA | 0.93 [0.89] | 0.93 [0.89] | [22] | SR [95% CI lower limit, conservative] |
VFA impossible | 0.03 [0.05] | 0.03 [0.05] | [22] | SR, per patient [per vertebrae] |
Costs (€)b | ||||
VFAc | 17 [40] | 17 [40] | [27] | 50% of X-ray test costs [Increase by 200% of X-ray costs, conservative] |
X-rayc | 24 [17] | 24 [17] | HIRA | EDI code, thoracic and lumbar spine in the AP and lateral |
VFs treatment | 1526 [1249] | 1707 [1336] | HIRA | NHI database, per patient [Mild VF relatively] |
Physician visits | 9 | 9 | HIRA | NHI database, per visit |
Drug therapy | 180 | 194 | HIRA | Drug weighted average charge, one-year administration |
Procedure | 809 | 934 | HIRA | NHI database, only in symptomatic VF cases |
Radiation doses (μSv) | ||||
X-ray | 600 | 600 | [12] | |
VFA | 25 [2] | 25 [2] | [12] | Average level of 2 to 50 μSv [lower limit] |